Parkinson's disease is characterised by a variable combination of tremor, rigidity, bradykinesia and impaired righting reflexes. The cumulative life-time risk is one in 40. Levodopa remains the single most effective treatment in older patients, and the minimum dose to achieve maxiumu functional benefit should be employed. When fluctuations occur, controlled release preparations and selegiline can improve function. Oral dopamine agonists have a role but the combined side effect profile with levodopa should be monitored. COMT inhibitors have recently become available. Subcutaneous apomorphine can be helpful when “on-off phenomema are marked. The concept of neuroprotection continues to be debated. Surgery is an option for fitter older people but neurotransplantation remains essentially a research tool.
Get full access to this article
View all access options for this article.
References
1.
D'AlessandroRGamberiniGGraniereF. Prevalence of Parkinson's disease in the Republic of San Marino. Neurology, 1987; 37: 1679–82.
2.
MutchWJDingwall-FordyceIDownieAW. Parkinson's disease in a Scottish city. Br Med J, 1986; 292: 534–36.
3.
HofmanAOttAde RijkMCBretelerMMB. Prevalence of Alzheimer's disease, vascular dementia, Parkinson's disease and epilepsy in a Dutch population study: The Rotterdam Study. Neuroepidemiology, 1995; 14: 312.
4.
BarbeuARoyM. Uneven prevalence of Parkinson's disease in the province of Quebec. Can J Neurol Sci, 1985; 12: 169–70.
5.
AquiloniusSMHartvigP. A Swedish county with unexpectedly high utilisation of antiParkinsonian drugs. Acta Neurol Scand, 1986; 74: 379–82.
6.
EbmeierKPMutchWJCalderSA. Does idiopathic Parkinsonism in Aberdeen follow intra-uterine influenza?J Neurol Neurosurg Psychiatry1989; 52, 911–13.
7.
KohbataSShimokawaK. Circulating antibody to Nocardia in the serum of patients with Parkinson's disease. Adv Neurol, 1993; 60: 355–57.
8.
de Pedro CuestaJPetersenIJStawiarzL. High levodopa use in periodically timeclustered, Icelandic birth cohorts: A vestige of Parkinsonian aetiology? Europarkinsonism Preparatory Activity Research Group. Acta Neurol Scand, 1995; 91: 79–88.
9.
SemchukKMLoveEJLeeRG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology, 1992; 42: 1328–35.
10.
HubbleJPCaoBSHassaneinRES. Risk factors for Parkinson's disease. Neurology, 1993; 43: 1693–97.
SmithCADGoughACLeighPN. Debrisoquine hydroxylase polymorphism and susceptibility to Parkinson's disease. Lancet, 1992; 339: 1375–77.
13.
GoughAC. Identification of the primary gene defect of the cytochrome P450, CYP2D locus. Nature, 1990; 347: 773.
14.
OlanowCWArendashGW. Metals and free radicals in neurodegeneration. Current Opinion in Neurology, 1994; 7: 548–58.
15.
BostantjopoulouSKyriazisGKatsarouZKiosseoglouGKazisAMentenopoulosG. Superoxide dismutase activity in early and advanced Parkinson's disease. Functional Neurology, 1997; 12: 63–68.
16.
JennerPOlanowCW. Oxidative stress and the pathogenesis of Parkinson's Disease. Neurology, 1996; 47(Suppl 3): 161–70.
17.
McGeerEGMcGeerPL. Inflammation cytokines in the CNS. Possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs, 1997; 7: 214–28.
18.
AngladePVyasSAgidJavoy F. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histology and Histopathology, 1997; 12, 25–31.
19.
KoselSEgenspergerRVon EitzenUMehraeinPGraeberMB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathologica, 1997; 93: 105–108.
20.
ZappiaMMontesantiRColaoR. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson'sDisease Movement Disorders1997; 12: 103–106.
21.
HughesAJLeesAJStemGM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet, 1990; 336: 32–34.
SawleGV. The detection of preclinical Parkinson's disease. Mov Disord, 1993; 8, 271–77.
24.
EidelbergDMoellerJRDhawanV. The metabolic topography of Parkinsonism. Journal of Cerebral Blood Flow and Metabolism, 1994; 14: 783–801.
25.
BruckeTAsenbaumSPirkerW. Measurement of the dopaminergic degeneration of Parkinson's disease with [1231]beta-CIT and SPECT. Journal of Neural Transmission1997; Supp 50: 9–24.
26.
BooijJTissinghGBoerGJSpeelmanJDStoofJCJanssenAGMWoltersE. [1231]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry, 1997; 62: 133–140.
27.
DotyRLBromleySMSternMB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: Development of optimal discrimination criteria. Neurodegeneration, 1995; 4: 93–97.
28.
AustenGoodwin RBFrearsCCTomlinsonEBKokHWL. Effects of L-dopa in Parkinson's disease. Lancet, 1969; ii: 165–68.
29.
TumbullCJAitkenJA. Diagnosis and management of Parkinsonism in the elderly. Age Ageing, 1983; 12: 309–316.
30.
SutcliffeRLG. L-dopa therapy in elderly patients with Parkinsonism. Age Ageing, 1973; 2: 34–38.
31.
WhiteNJBarnesTRE. Senile Parkinsonism: A survey of current treatment. Age Ageing, 1981; 10, 81–86.
32.
WilsonJASmithRG. The prevalence and aetiology of long-term L-dopa side effects in elderly Parkinsonian patients. Age Ageing, 1989; 18: 11–16.
33.
QuinnNP. A case against early levodopa treatment of Parkinson's disease. Clinical Neuropharmacology, 1995; 18(Suppl 3): 43–49.
34.
CaraceniT. A case for early levodopa treatment of Parkinson's disease. Clinical Neuropharmacology, 1995; 18(Suppl 3): 38–42.
35.
FahnS. Is levodopa toxic?Neurology1996; 47(Suppl 3): 184–95.
36.
DupontEAndersenABoasJ. Sustained-release Madopar HBS(R) compared with standard Madopar (R) in the long-term treatment of de novo parkinsonian patients. Acta Neurologica Scandinavica, 1996; 93: 14–20.
37.
BlockGLissCReinesS. Comparison of immediate-release and controlled release Carbidopa/Levodopa in Parkinson's disease. A multicenter 5-year study. European Neurology, 1997; 37: 23–27.
38.
LissCBushDLastBSmithBBlockGReinesS. CR FIRST: An interim report of a 5year clinical study in patients with Parkinson's disease with no prior levodopa therapy. Clinical Drug Investigation, 1997; 13: 15–22.
39.
ZieglerMRanouxDde RecondoJ. Clinical efficacy of a liquid formulation of levodopa (Madopar dispersible) in reversing afternoon ‘off’ periods in Parkinson's disease. Clin Neuropharmacol, 1994; 17(Suppl 3): 21–25.
40.
WaltersJWBergstromDACarlsonJH. Dl dopamine receptor activation required for post-synaptic expression of D2 agonist effects. Science, 1987; 236: 719–22.
41.
RabeyJM. Late addition of dopamine agonists in Parkinson's disease. p.283. In RinneUKNagatsuTHorowskiR (eds): How to proceed today in treatment. International Workshop Berlin Parkinson's Disease. Medicom Europe BV: Bussum1991.
42.
PezzoliGMartignoniEPacchettiC. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover controlled study. Movement Disorders, 1994; 9: 431–36.
43.
NuttJGHamrnerstadJPGancherST. Therapy: Dopamine agonists in Parkinson's disease 100 maxims. London, Edward Arnold, 1992.
44.
PrzuntekHWelzelDGerlachM. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long term results of the PRADO study. J Neural Transm, 1996; 103: 699–715.
45.
MearaRJCassidyTPDunnAHindleJHuggettIMMedcalfPMorrisJSharmaJCStaintonAHobsonJP(The pergolide study group). The role of pergolide in the treatment of Parkinson's disease in the elderly. Age and Ageing, 1997; 26(Suppl 1): 15.
46.
SteigerMJEldebasTAndersonTFindleyLJMarsdenCD. Double blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. Journal of Neurology, 1996; 243: 68–72.
47.
GeminianiGFetoniVGenitriniSGiovanniniPTammaFCaraceniT. Cabergoline in Parkinson's disease complicated by motor fluctuations. Movement Disorders, 1996; 11: 495–500.
48.
KurthMCAdlerCHSt HilaireM. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicentre, double-blind, randomised, placebo-controlled trial. Neurology, 1997; 48: 81–87.
49.
RuottinenHMRinneUK. Effect of one-month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clinical Neuropharmacology, 1996; 19: 222–33.
50.
MyllylaWSotaniemicKAVuorinenJAHeinonenEA. Selegiline in de novo parkinsonian patients; the Finnish study. Mov Disord, 1993; 8(Suppl 1): 541–44.
51.
Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J, 1995; 311: 1602–07.
52.
LeesAJFrankelJEatoughVSternGM. New approached in the use of selegiline for the treatment of Parkinson's disease. Acta Neurol Scand, 1989; 80(Suppl 126): 139–45.
53.
ZornbergGL. Severe adverse interaction between pethidine and selegiline. Lancet, 1991; 337: 246.
54.
SuchowerskyAde VriesJD. Interaction of fluoxitene and selegiline. Can J Psychol, 1990; 35: 571.
55.
TolosaEValldeoriolaF. Mid-stage Parkinsonism with mild motor fluctuations. Clin Neuropharmacol, 1994; 17(Suppl 2): 19–31.
56.
MouradianMMJuncosJLFabbriniG. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms 11. Ann Neurol, 1988; 24: 372–78.
57.
SageJIMarkMH. Basic mechanisms of motor fluctuations. Neurology, 1994; 44(Suppl 6): 10–14.
58.
BirkmeyerWRiedererPYoudimMBH. (-)Deprenyl in the treatment of Parkinson's disease. ClinNeuropharmacol, 1982; 5: 195–230.
59.
PahwaRBusenbarkRNHuberSJ. Clinical experience with controlled-release carbidopallevodopa in Parkinson's disease. Neurology, 1993; 43: 677–81.
RinneUK. Strategies in the treatment of early Parkinson's disease. Acta Neurol Scand, 1993; 87(Suppl 146): 50–53.
62.
MontastrucJLRascolOSenardJMRascolA. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow-up. J Neurol Neurosurg Psychiatry, 1994; 57: 1034–38.
63.
WeinerWJFactorSASanchez-RamosJR. Early combination (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology, 1993; 43: 21–27.
64.
GoetzCG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology, 1990; 40(Suppl 1): 50–54.
65.
HughesAJBishopSKleedorferB. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years. Mov Disord, 1993; 8: 165–70.
66.
MunozJEMartiMJMarinCTolosaE. Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations. Clinical Neuropharmacology, 1997, 20: 245–52.
67.
BirkmeyerWKnollJRiedererP. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study. J Neural Transm, 1985; 64: 113–27.
68.
OlanowCW. A scientific rationale for protective therapy in Parkinson's disease. J Neural Transm, 1993; 91: 161–80.
69.
The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. NEngl JMed, 1989; 321: 1364–71.
70.
The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 1993; 328: 176–83.
71.
LeesAJHeadJShlomoBen Y. Selegiline and mortality in Parkinson's disease: Another view. Ann of Neurology, 1997; 41: 282–83.
72.
OlanowCWFahnSLangstonMDGodboldJ. Selegiline and mortality in Parkinson's disease. Ann of Neurology, 1996; 40: 841–45.
73.
CarrilloMCKanaiSSatoYIvyGOKitaniK. Sequential changes in activities of superoxide dismutase and catalas in brain regions and liver during (-) deprenyl infusion in male rats. Biochem Pharmacol, 1992; 44: 2185–89.
74.
TattonWGChalmers-RedmanRME. Modulation of gene expression rather than monoamino oxidase inhibition: (-) deprenyl-related compounds in controlling neurodegeneration. Neurology, 1996; 47: 171–83.
75.
OlanowCWHauserRAGaugerI. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol, 1996; 40: 269.
76.
SweetRDLeeJESpiegelHEMcDowellFEnhanced response to low doses of levodopa after withdrawal from treatment. Neurology1972; 22: 520–25.
77.
MayeuxRSternYMulveyKCoteL. Re-appraisal of temporary levodopa withdrawal (‘drug holiday’) in Parkinson's disease. N Engl J Med, 1985; 313, 724–28.
78.
BenabidAlPollakPGervasonC. Long-term supression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet, 1991; 337, 403–406.
79.
ShibazakiTHiraiTHiratoY. Physiologically identified, selective ventrointermedius thalamotomy ameliorates, various kinds of tremor and other disorders of movement related to tremor, p. 393. In CrossmanARSambrookMA (eds): Neural Mechanisms in Disorders of Movement: Current Problems in Neurology 9. John Libbey, London, 1989.
80.
LaitinenLVBergenheimnATHanzMI. Leskell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg, 1992; 76: 53–61.
81.
MarsdenCDObesoJA. The functions of the basal ganglia and the paradox of stereotactic surgery in Parkinson's disease. Brain, 1994; 117: 877–97.
82.
LindvallO. Neural transplantation in Parkinson's disease, p. 103. In DunnettSBBjorklundA (eds): Functional neural transplantation. Raven Press, New York, 1991.
83.
LindvallOWidnerHRehncronaP. Transplantation of fetal dopaminergic neurons in Parkinson's disease: One year clinical and neuropsychological observations in two patients with putamenal implants. Ann Neurol, 1992; 31: 155–65.
84.
JiaoSGurevichVWolffJA. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature, 1993; 362: 450–53.
